GSK presents positive data for AREXVY, its respiratory syncytial virus ...
WEB2 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults …
GSK says RSV vaccine protects against disease over three seasons
WEB2 days ago · Dive Brief: Vaccine maker GSK unveiled new data Tuesday showing its respiratory syncytial virus vaccine Arexvy protected older adults over three seasons against disease caused by infection. Across the entire time period, one dose of Arexvy was 63% effective against RSV broadly, and 67% effective against severe disease, GSK said.
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus ...
WEB2 days ago · Today's results indicate that after a single dose of GSK’s RSV vaccine, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD (97.5% CI, 46.7-74.8 ...
GSK Says RSV Vaccine Offers Protection Over Three Seasons
WEB2 days ago · 1:42. GSK Plc’s shot for respiratory syncytial virus provided protection across three seasons after vaccination, the company said Tuesday. The shot for older adults showed cumulative efficacy ...
GSK reports positive findings from Phase III RSV vaccine trial
WEB1 day ago · GSK has unveiled positive data from its Phase III AReSVi-006 clinical trial of Arexvy, its respiratory syncytial virus (RSV) vaccine, which aims to prevent lower respiratory tract disease (LRTD) over three RSV seasons. The trial, involving approximately 25,000 participants from 17 countries, focused on adults aged 60 years and older, …
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus ...
WEB2 days ago · Today's results indicate that after a single dose of GSK’s RSV vaccine, cumulative efficacy over three full RSV seasons was clinically meaningful at 62.9% against RSV-LRTD (97.5% CI, 46.7-74.8, 48 of 12,468 vs 215 of 12,498) and 67.4% against severe RSV-LRTD (95% CI, 42.4-82.7, 15 of 12,468 vs 75 of 12,498) compared to placebo.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · Respiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01 E adjuvant. In the US, AREXVY is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older.
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
WEBOct 25, 2023 · New data for AREXVY, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease. Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59 compared to adults aged 60 and older.
GSK’s older adult respiratory syncytial virus (RSV) vaccine …
WEBOct 13, 2022 · High vaccine efficacy is consistent across RSV A and B strains. GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
- Some results have been removed